Comparison of Secukinumab 300 mg Combined With a Lifestyle Intervention to Secukinumab Alone for the Treatment of Moderate to Severe Psoriasis Patients With Concomitant Metabolic Syndrome

NCT03440736 · clinicaltrials.gov ↗

PHASE4

Phase

COMPLETED

Status

781

Enrollment

INDUSTRY

Sponsor class

Conditions

Psoriasis
Metabolic Syndrome

Interventions

DRUG: Secukinumab
BEHAVIORAL: Life-style intervention

Sponsor

Novartis Pharmaceuticals